⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78549 | 1.00 | — | — | |
| SCHEMBL78548 | 1.00 | — | — | |
| SCHEMBL6129633 | 0.96 | — | — | |
| SCHEMBL7936373 | 0.96 | — | — | |
| SCHEMBL7530900 | 0.87 | — | — | |
| Bicarbonate SCHEMBL11391548 | 0.84 | — | — | |
| SCHEMBL15684340 | 0.74 | — | — | |
| SCHEMBL6992955 | 0.74 | — | — | |
| SCHEMBL6992958 | 0.74 | — | — | |
| SCHEMBL15699938 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138947-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260042735-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20240400510-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4423061-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | Reunion Neuroscience, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118382614-A | Novel benzyl tryptamine compounds | 瑞安神经科学公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20230144974-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144974-A1 | BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023070228-A1 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | REUNION NEUROSCIENCE CANADA INC. (CA) | 2023-05-04 | — | — | WO | disclosed |
| WO-2016045550-A1 | TGFβ SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE | HONG GUAN LTD. (CN) | 2016-03-31 | — | — | WO | disclosed |
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | disclosed |
| EP-1268450-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020137737-A1 | Lactams substituted by cyclic succinates as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-26 | — | — | US | disclosed |
| WO-2002012223-A2 | SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001092235-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
| EP-0000554-A1 | Process for the preparation of oxiranes substituted by halogen alkyl | BAYER AG (DE) | 1979-02-07 | — | — | EP | disclosed |
| US-3953377-A | Ethyl-2-trans-4-cis undecadienoate, ethyl-2-trans-4-cis dodecadienoate and ethyl-2-decadienoate perfume compositions | FIRMENICH S.A. (CH) | 1976-04-27 | — | — | US | disclosed |